DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|rareLife solutions 606 Post Road East #397
Westport, CT 06880
|You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
Alexion Pharmaceuticals (ALXN) has been one of the greatest growth stories in the ultra-rare disease space over the past decade, with their blockbuster C5 inhibitor, Soliris, growing sales to nearly $4 billion in 2018. Although the company still managed to grow top-line revenue by more than 19% in 2018 (without any price increases), market share in their lead indications of PNH and aHUS is becoming somewhat saturated, and they are looking for new growth avenues.
In an effort to continue executing on this goal, on January 31st, Alexion Pharmaceuticals entered into a partnership with Caelum Biosciences (a Fortress Biotech (FBIO) company) to co-develop their lead asset for the treatment of Light-Chain Amyloidosis. This is Alexion’s first endeavor in treating amyloidosis, and I believe the partnership could be one of their most lucrative to date.
people & placesVaishali Sanchorawala, MDVaishali Sanchorawala is the Director of...
people & placesNorthwestern Medicine Amyloid ProgramThe Amyloid Program at Northwestern Medi...
people & placesBarnes-Jewish Hospital, Washington University Amyloid CenterAt the Washington University Amyloid Cen...
educationWhat is New in Diagnosis and Management of Light Chain Amyloidosis?Light chain (AL) amyloidosis is caused b...
news & meetingsJanssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (Daratumumab and Hyaluronidase-fihj) for...The Janssen Pharmaceutical Companies of ...
educationMarked Progress in AL Amyloidosis Survival: A 40-Year Longitudinal Natural History StudyThe recent decades have ushered in consi...
educationCase Report: Treatment of Light-Chain Amyloidosis With Daratumumab Monotherapy in Two PatientsImmunoglobulin light-chain amyloidosis (...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.